

# Hermann M SchÄtztzl

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9561914/publications.pdf>

Version: 2024-02-01

127  
papers

13,030  
citations

94433

37  
h-index

23533

111  
g-index

135  
all docs

135  
docs citations

135  
times ranked

23992  
citing authors

#	ARTICLE	IF	CITATIONS
1	Astrocyte in prion disease: a double-edged sword. <i>Neural Regeneration Research</i> , 2022, 17, 1659.	3.0	12
2	Gene-Edited Cell Models to Study Chronic Wasting Disease. <i>Viruses</i> , 2022, 14, 609.	3.3	0
3	Clearance of variant Creutzfeldt-Jakob disease prions <i>in vivo</i> by the Hsp70 disaggregase system. <i>Brain</i> , 2022, 145, 3236-3249.	7.6	6
4	Early detection of prion protein aggregation with a fluorescent pentameric oligothiophene probe using spectral confocal microscopy. <i>Journal of Neurochemistry</i> , 2021, 156, 1033-1048.	3.9	9
5	Cervid Prion Protein Polymorphisms: Role in Chronic Wasting Disease Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2271.	4.1	29
6	Polymorphisms in glia maturation factor $\beta^2$ gene are markers of cellulose ether effectiveness in prion-infected mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 560, 105-111.	2.1	4
7	Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies. <i>Science Advances</i> , 2021, 7, eabj1826.	10.3	18
8	Cellulose ether treatment <i>in vivo</i> generates chronic wasting disease prions with reduced protease resistance and delayed disease progression. <i>Journal of Neurochemistry</i> , 2020, 152, 727-740.	3.9	14
9	Metformin reduces prion infection in neuronal cells by enhancing autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 423-428.	2.1	12
10	An astrocyte cell line that differentially propagates murine prions. <i>Journal of Biological Chemistry</i> , 2020, 295, 11572-11583.	3.4	18
11	From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins. <i>Biomolecules</i> , 2020, 10, 1305.	4.0	12
12	Sephin1 Reduces Prion Infection in Prion-Infected Cells and Animal Model. <i>Molecular Neurobiology</i> , 2020, 57, 2206-2219.	4.0	11
13	Gene-edited murine cell lines for propagation of chronic wasting disease prions. <i>Scientific Reports</i> , 2019, 9, 11151.	3.3	17
14	Preparation and Characterization of Cellulose Ether Liposomes for the Inhibition of Prion Formation in Prion-Infected Cells. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2814-2820.	3.3	7
15	Combining autophagy stimulators and cellulose ethers for therapy against prion disease. <i>Prion</i> , 2019, 13, 185-196.	1.8	21
16	Autophagy pathways in the treatment of prion diseases. <i>Current Opinion in Pharmacology</i> , 2019, 44, 46-52.	3.5	22
17	Dimerization of the cellular prion protein inhibits propagation of scrapie prions. <i>Journal of Biological Chemistry</i> , 2018, 293, 8020-8031.	3.4	13
18	Autophagy regulates exosomal release of prions in neuronal cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 8956-8968.	3.4	82

#	ARTICLE	IF	CITATIONS
19	Recombinant prion protein vaccination of transgenic elk PrP mice and reindeer overcomes self-tolerance and protects mice against chronic wasting disease. <i>Journal of Biological Chemistry</i> , 2018, 293, 19812-19822.	3.4	14
20	Overexpression of quality control proteins reduces prion conversion in prion-infected cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 16069-16082.	3.4	11
21	Disulfide-crosslink scanning reveals prion-specific induced conformational changes and prion strain-specific structures of the pathological prion protein PrP <sup>Sc</sup> . <i>Journal of Biological Chemistry</i> , 2018, 293, 12730-12740.	3.4	11
22	The autophagy inducers AR-12 and AR-14 control prion infection. <i>FASEB Journal</i> , 2018, 32, 795.5.	0.5	0
23	Immunization of cervidized transgenic mice with multimeric deer prion protein induces self-antibodies that antagonize chronic wasting disease infectivity in vitro. <i>Scientific Reports</i> , 2017, 7, 10538.	3.3	14
24	Prion strains depend on different endocytic routes for productive infection. <i>Scientific Reports</i> , 2017, 7, 6923.	3.3	29
25	The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions. <i>Scientific Reports</i> , 2017, 7, 17565.	3.3	24
26	Endemic chronic wasting disease causes mule deer population decline in Wyoming. <i>PLoS ONE</i> , 2017, 12, e0186512.	2.5	77
27	Chronic wasting disease: Emerging prions and their potential risk. <i>PLoS Pathogens</i> , 2017, 13, e1006619.	4.7	57
28	Prion infection impairs lysosomal degradation capacity by interfering with rab7 membrane attachment in neuronal cells. <i>Scientific Reports</i> , 2016, 6, 21658.	3.3	33
29	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
30	LRP/LR Antibody Mediated Rescuing of Amyloid- $\beta$ -Induced Cytotoxicity is Dependent on PrP <sup>c</sup> in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 645-657.	2.6	24
31	Modulation of Glycosaminoglycans Affects PrP <sup>Sc</sup> Metabolism but Does Not Block PrP <sup>Sc</sup> Uptake. <i>Journal of Virology</i> , 2015, 89, 9853-9864.	3.4	15
32	Small-scale Triton X-114 Extraction of Hydrophobic Proteins. <i>Bio-protocol</i> , 2014, 4, .	0.4	18
33	Assessing Proteinase K Resistance of Fish Prion Proteins in a Scrapie-Infected Mouse Neuroblastoma Cell Line. <i>Viruses</i> , 2014, 6, 4398-4421.	3.3	5
34	Piperazine derivatives inhibit PrP/PrP <sup>Sc</sup> propagation in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 23-29.	2.1	9
35	Small-scale Subcellular Fractionation with Sucrose Step Gradient. <i>Bio-protocol</i> , 2014, 4, .	0.4	2
36	Identifying critical sites of PrP <sup>c</sup> -PrP <sup>Sc</sup> interaction in prion-infected cells by dominant-negative inhibition. <i>Prion</i> , 2013, 7, 452-456.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Critical Significance of the Region between Helix 1 and 2 for Efficient Dominant-Negative Inhibition by Conversion-Incompetent Prion Protein. <i>PLoS Pathogens</i> , 2013, 9, e1003466.	4.7	25
38	Early detection of chronic wasting disease prions in urine of pre-symptomatic deer by real-time quaking-induced conversion assay. <i>Prion</i> , 2013, 7, 253-258.	1.8	68
39	Cell-to-cell propagation of infectious cytosolic protein aggregates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5951-5956.	7.1	45
40	Introducing a Rigid Loop Structure from Deer into Mouse Prion Protein Increases Its Propensity for Misfolding In Vitro. <i>PLoS ONE</i> , 2013, 8, e66715.	2.5	11
41	Cellular Mechanisms of Propagation and Clearance. , 2013, , 147-160.		1
42	Prions. , 2013, , 919-947.		0
43	Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain. <i>Journal of Virology</i> , 2012, 86, 10112-10122.	3.4	130
44	Failure of Prion Protein Oxidative Folding Guides the Formation of Toxic Transmembrane Forms. <i>Journal of Biological Chemistry</i> , 2012, 287, 36693-36701.	3.4	12
45	A genome-wide survey for prion-regulated miRNAs associated with cholesterol homeostasis. <i>BMC Genomics</i> , 2012, 13, 486.	2.8	13
46	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
47	Detection of PrPSc in peripheral tissues of clinically affected cattle after oral challenge with bovine spongiform encephalopathy. <i>Journal of General Virology</i> , 2012, 93, 2740-2748.	2.9	34
48	Parvovirus B19 and necrotizing enterocolitis in neonates. <i>Journal of Pediatrics</i> , 2012, 160, 887.	1.8	0
49	From High-Throughput Cell Culture Screening to Mouse Model: Identification of New Inhibitor Classes against Prion Disease. <i>ChemMedChem</i> , 2011, 6, 1928-1937.	3.2	21
50	Conditional Modulation of Membrane Protein Expression in Cultured Cells Mediated by Prion Protein Recognition of Short Phosphorothioate Oligodeoxynucleotides. <i>Journal of Biological Chemistry</i> , 2011, 286, 6911-6917.	3.4	6
51	Proteasomal Dysfunction and Endoplasmic Reticulum Stress Enhance Trafficking of Prion Protein Aggregates through the Secretory Pathway and Increase Accumulation of Pathologic Prion Protein. <i>Journal of Biological Chemistry</i> , 2011, 286, 33942-33953.	3.4	50
52	Diphenylpyrazole-Derived Compounds Increase Survival Time of Mice after Prion Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4774-4781.	3.2	12
53	Chronic Wasting Disease. <i>Topics in Current Chemistry</i> , 2011, 305, 51-77.	4.0	69
54	GABAA receptor subunit $\gamma 2$ is involved in the formation of protease-resistant prion protein in prion-infected neuroblastoma cells. <i>FEBS Letters</i> , 2010, 584, 1193-1198.	2.8	4

#	ARTICLE	IF	CITATIONS
55	Elevated Epstein-Barr virus loads and lower antibody titers in competitive athletes. <i>Journal of Medical Virology</i> , 2010, 82, 446-451.	5.0	15
56	Isolated norovirus GII.7 strain within an extended GII.4 outbreak. <i>Journal of Medical Virology</i> , 2010, 82, 1058-1064.	5.0	9
57	Modulation of Host Cell Death by SARS Coronavirus Proteins. , 2010, , 231-245.		5
58	Prionen. , 2010, , 667-685.		0
59	Autophagy, prion infection and their mutual interactions. <i>Current Issues in Molecular Biology</i> , 2010, 12, 87-97.	2.4	86
60	Inhibition of Prion Amplification by Expression of Dominant Inhibitory Mutants - A Systematic Insertion Mutagenesis Study. <i>Infectious Disorders - Drug Targets</i> , 2009, 9, 40-47.	0.8	7
61	Therapy in Prion Diseases: From Molecular and Cellular Biology to Therapeutic Targets. <i>Infectious Disorders - Drug Targets</i> , 2009, 9, 3-14.	0.8	19
62	The yeast Sup35NM domain propagates as a prion in mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 462-467.	7.1	65
63	Prion-induced Activation of Cholesterologenic Gene Expression by Srebp2 in Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 31260-31269.	3.4	34
64	Prion-like propagation of cytosolic protein aggregates. <i>Prion</i> , 2009, 3, 206-212.	1.8	43
65	Aptamers against prion proteins and prions. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 2445-2455.	5.4	28
66	Inhibition of cholesterol recycling impairs cellular PrP <sup>Sc</sup> propagation. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 3979-3991.	5.4	37
67	Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. <i>Journal of Neurochemistry</i> , 2009, 109, 25-34.	3.9	169
68	Autophagy induction by trehalose counter-acts cellular prion-infection. <i>Autophagy</i> , 2009, 5, 361-369.	9.1	198
69	The Novel Sorting Nexin SNX33 Interferes with Cellular PrP <sup>Sc</sup> Formation by Modulation of PrP <sup>Sc</sup> Shedding. <i>Traffic</i> , 2008, 9, 1116-1129.	2.7	29
70	The octarepeat region of prion protein, but not the TM1 domain, is important for the antioxidant effect of prion protein. <i>Free Radical Biology and Medicine</i> , 2008, 45, 1622-1630.	2.9	13
71	Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrP <sup>c</sup> . <i>Molecular and Cellular Neurosciences</i> , 2008, 38, 98-109.	2.2	6
72	Cell Type-Specific Cleavage of Nucleocapsid Protein by Effector Caspases during SARS Coronavirus Infection. <i>Journal of Molecular Biology</i> , 2008, 376, 23-34.	4.2	37

#	ARTICLE	IF	CITATIONS
73	A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. <i>Vaccine</i> , 2008, 26, 6678-6684.	3.8	23
74	Therapeutic vaccination reduces HIV sequence variability. <i>FASEB Journal</i> , 2008, 22, 437-444.	0.5	9
75	Dynamic interactions of Sup35p and PrP prion protein domains modulate aggregate nucleation and seeding. <i>Prion</i> , 2008, 2, 99-106.	1.8	10
76	Prion protein/protein interactions: fusion with yeast Sup35p $\Delta$ NM modulates cytosolic PrP aggregation in mammalian cells. <i>FASEB Journal</i> , 2008, 22, 762-773.	0.5	17
77	Targeting prion proteins in neurodegenerative disease. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 923-940.	3.1	11
78	Scrapie Infection of Prion Protein-deficient Cell Line upon Ectopic Expression of Mutant Prion Proteins. <i>Journal of Biological Chemistry</i> , 2007, 282, 18702-18710.	3.4	34
79	In Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers. <i>PLoS Pathogens</i> , 2007, 3, e125.	4.7	201
80	Poly(lactide-Coglycolide) Microspheres Co-encapsulating Recombinant Tandem Prion Protein with CpG-Oligonucleotide Break Self-Tolerance to Prion Protein in Wild-Type Mice and Induce CD4 and CD8 T Cell Responses. <i>Journal of Immunology</i> , 2007, 179, 2797-2807.	0.8	50
81	Toxic Effects of Intracerebral PrP Antibody Administration During the Course of BSE Infection in Mice. <i>Prion</i> , 2007, 1, 198-206.	1.8	28
82	Concomitant Administration of a Virosome-Adjuvanted Hepatitis A Vaccine With Routine Childhood Vaccines at Age Twelve to Fifteen Months: A Randomized Controlled Trial. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 787-793.	2.0	34
83	Peptide Aptamers Expressed in the Secretory Pathway Interfere with Cellular PrP <sup>Sc</sup> Formation. <i>Journal of Molecular Biology</i> , 2007, 371, 362-373.	4.2	25
84	Evaluation of Modified Vaccinia Virus Ankara as an Alternative Vaccine against Smallpox in Chronically HIV Type 1-Infected Individuals Undergoing HAART. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 782-793.	1.1	27
85	The anticancer drug imatinib induces cellular autophagy. <i>Leukemia</i> , 2007, 21, 936-942.	7.2	208
86	Molecular basis of cerebral neurodegeneration in prion diseases. <i>FEBS Journal</i> , 2007, 274, 606-611.	4.7	33
87	Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. <i>FEBS Journal</i> , 2007, 274, 1747-1758.	4.7	42
88	CpG and LPS can interfere negatively with prion clearance in macrophage and microglial cells. <i>FEBS Journal</i> , 2007, 274, 5834-5844.	4.7	21
89	Strategies for eliminating PrP <sup>C</sup> as substrate for prion conversion and for enhancing PrP <sup>Sc</sup> degradation. <i>Veterinary Microbiology</i> , 2007, 123, 377-386.	1.9	13
90	The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. <i>Journal of NeuroVirology</i> , 2007, 13, 328-337.	2.1	40

#	ARTICLE	IF	CITATIONS
91	Antibodies to a Nonconjugated Prion Protein Peptide 95-123 Interfere with PrP Sc Propagation in Prion-Infected Cells. <i>Cellular and Molecular Neurobiology</i> , 2007, 27, 271-284.	3.3	14
92	Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia. <i>Haematologica</i> , 2007, 92, 1282-1283.	3.5	8
93	Prion infection influences murine endogenous retrovirus expression in neuronal cells. <i>Biochemical and Biophysical Research Communications</i> , 2006, 343, 825-831.	2.1	13
94	The prion protein requires cholesterol for cell surface localization. <i>Molecular and Cellular Neurosciences</i> , 2006, 31, 346-353.	2.2	62
95	The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. <i>Journal of Medical Virology</i> , 2006, 78, 311-317.	5.0	21
96	Ultra-sensitive detection of prion protein fibrils by flow cytometry in blood from cattle affected with bovine spongiform encephalopathy. <i>BMC Biotechnology</i> , 2005, 5, 26.	3.3	26
97	Genomic Characterization of a Novel HIV Type 1 B/G Intersubtype Recombinant Strain from an Injecting Drug User in Germany. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 654-660.	1.1	9
98	Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. <i>Journal of Cell Science</i> , 2005, 118, 4959-4973.	2.0	32
99	Cell Line Dependent RNA Expression Profiles of Prion-infected Mouse Neuronal Cells. <i>Journal of Molecular Biology</i> , 2005, 349, 487-500.	4.2	47
100	Insights into the Cellular Trafficking of Prion Proteins. , 2005, , 379-405.		0
101	Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14670-14676.	7.1	105
102	The Tyrosine Kinase Inhibitor STI571 Induces Cellular Clearance of PrPSc in Prion-infected Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 41918-41927.	3.4	114
103	Glycosylation Deficiency at Either One of the Two Glycan Attachment Sites of Cellular Prion Protein Preserves Susceptibility to Bovine Spongiform Encephalopathy and Scrapie Infections. <i>Journal of Biological Chemistry</i> , 2004, 279, 53306-53316.	3.4	62
104	Recognition of Luminal Prion Protein Aggregates by Post-ER Quality Control Mechanisms Is Mediated by the Prooctarepeat Region of PrP. <i>Traffic</i> , 2004, 5, 300-313.	2.7	19
105	Prion Diseases: From Molecular Biology to Intervention Strategies. <i>ChemBioChem</i> , 2003, 4, 1268-1284.	2.6	37
106	Promising developments bringing prion diseases closer to therapy and prophylaxis. <i>Trends in Molecular Medicine</i> , 2003, 9, 367-369.	6.7	14
107	Essential Role of the Prion Protein N Terminus in Subcellular Trafficking and Half-life of Cellular Prion Protein. <i>Journal of Biological Chemistry</i> , 2003, 278, 3726-3734.	3.4	97
108	Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrPSc Propagation in Prion-infected Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 18524-18531.	3.4	99

#	ARTICLE	IF	CITATIONS
109	Stability and conformational properties of doppel, a prion-like protein, and its single-disulphide mutant. <i>Biochemical Journal</i> , 2003, 373, 485-494.	3.7	18
110	Prion-Protein-Specific Aptamer Reduces PrPSc Formation. <i>ChemBioChem</i> , 2002, 3, 717.	2.6	141
111	Prominent Stress Response of Purkinje Cells in Creutzfeldt-Jakob Disease. <i>Neurobiology of Disease</i> , 2001, 8, 881-889.	4.4	29
112	Intracellular re-routing of prion protein prevents propagation of PrPSc and delays onset of prion disease. <i>EMBO Journal</i> , 2001, 20, 3957-3966.	7.8	147
113	PrPC Directly Interacts with Proteins Involved in Signaling Pathways. <i>Journal of Biological Chemistry</i> , 2001, 276, 44604-44612.	3.4	185
114	Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein 1 Edited by A. R. Fersht. <i>Journal of Molecular Biology</i> , 1999, 289, 1163-1178.	4.2	382
115	Is codon 129 of prion protein polymorphic in human beings but not in animals?. <i>Lancet, The</i> , 1997, 349, 1603-1604.	13.7	47
116	Variability of the Hepatitis B Surface Protein in HBV-Infected Liver Transplant Recipients. <i>Journal of Biomedical Science</i> , 1997, 4, 146-154.	7.0	0
117	Variability of the hepatitis B surface protein in HBV-infected liver transplant recipients. <i>Journal of Biomedical Science</i> , 1997, 4, 146-154.	7.0	8
118	Sequence Note: Phylogenetic Characterization of Simian T Lymphotropic Virus Type I (STLV-I) from the Ethiopian Sacred Baboon ( <i>Papio hamadryas</i> ). <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 255-258.	1.1	17
119	Quantification of hepatitis B virus DNA over a wide range from serum for studying viral replicative activity in response to treatment and in recurrent infection. <i>Hepatology</i> , 1995, 21, 1492-1499.	7.3	47
120	Neurotrophic factors: ready to go?. <i>Trends in Neurosciences</i> , 1995, 18, 463-464.	8.6	20
121	Prion Protein Gene Variation Among Primates. <i>Journal of Molecular Biology</i> , 1995, 245, 362-374.	4.2	309
122	Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: high percentage of carriers of hepatitis B and C virus. <i>Journal of Hepatology</i> , 1995, 23, 14-20.	3.7	157
123	Prevalence of human T-Cell lymphotropic virus infections in Germany. <i>Journal of Medical Virology</i> , 1994, 43, 159-160.	5.0	6
124	The immune response to different doses of inactivated hepatitis A vaccine. <i>Journal of Hepatology</i> , 1993, 18, S38-S40.	3.7	5
125	A Seroepidemiological Survey of Antibodies to HTLV-I/ HTLV-II in Selected Population Groups in Paraguay. <i>Scandinavian Journal of Infectious Diseases</i> , 1992, 24, 397-398.	1.5	7
126	Vaccination against hepatitis A: comparison of different short-term immunization schedules. <i>Vaccine</i> , 1992, 10, S126-S128.	3.8	19



#	ARTICLE	IF	CITATIONS
127	Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor. Archives of Virology, 1991, 120, 71-81.	2.1	55